©Author(s) (or their employer(s)) 2026.
World J Crit Care Med. Mar 9, 2026; 15(1): 114225
Published online Mar 9, 2026. doi: 10.5492/wjccm.v15.i1.114225
Published online Mar 9, 2026. doi: 10.5492/wjccm.v15.i1.114225
Table 1 Summary of studies on the diagnostic role of microRNAs in sepsis and septic shock
| Ref. | Year | Study type | Up/downregulated | Area under the curve | MicroRNAs | Diagnostic purpose | Sample size |
| García-Concejo et al[14] | 2025 | Prospective multicenter observational study | Down | 0.960 (validation) | MiR-451a, miR-100-5p, miR-148a-3p | Differentiating septic shock from non-septic shock | 161 (109 discovery, 52 validation) |
| Ye et al[15] | 2025 | Prospective observational cohort study | Up | 0.825 (sepsis), 0.821 (septic shock) | MiR-9-5p | Predicting sepsis and septic shock | 134 (69 sepsis, 30 non-sepsis, 35 healthy) |
| Li et al[13] | 2025 | Prospective observational study | Down | 13.17 | MiR-193b-5p | Distinguishing sepsis from healthy conditions | 105 (15 exploratory, 90 validation) |
| Behroozizad et al[16] | 2024 | Case-control study | Up | 1.25 | MiR-135a | Independent predictor of sepsis | 200 (100 sepsis, 100 healthy) |
| Li et al[17] | 2025 | Case-control study | Up | 14.39 | MiR-181a-5p | Biomarker for sepsis | 244 (119 sepsis, 125 healthy) |
Table 2 Summary of studies on the prognostic and therapeutic monitoring role of microRNAs in sepsis and septic shock
| Ref. | Year | Study type | Up/downregulated | AUC/HR/OR | MicroRNAs | Prognostic/therapeutic purpose | Sample size |
| Wang et al[22] | 2024 | Retrospective clinical study | Down (post-treatment) | Not specified | MiR-155, miR-146a | Monitoring treatment efficacy (ulinastatin + HBPT) | 150 (77 HBPT + ulinastatin, 73 HBPT) |
| Fan et al[23] | 2024 | Prospective cohort study | Up (in SAKI) | OR = 1.21 | MiR-155 | Prognosis of SAKI and 28-day mortality | 150 (79 SAKI, 71 septic non-acute kidney injury) |
| Zhang et al[24] | 2025 | Prospective cohort study | Up (lower levels = better survival) | AUC = 0.735 | MiR-182 | Predicting 28-day mortality | 178 (128 sepsis, 50 healthy) |
| Liu et al[25] | 2024 | Longitudinal study | Fluctuates | AUC = 0.72 (for miR-497) | MiR-195, MiR-497 | Guiding timing of immunotherapy/predicting mortality | 10 (120 collected samples) |
| Cheng et al[26] | 2025 | Prospective single-center cohort study | Down (reduced levels = poor prognosis) | HR = 3.063, AUC = 0.691 | MiR-146b-5p | Independent predictor of 28-day mortality | 191 septic patients |
| Mao et al[27] | 2023 | Observational clinical study | Down (in ALI) | AUC = 0.777 | MiR-126-5p | Prognostic factor for sepsis-induced ALI | 240 (120 sepsis, 120 healthy) |
- Citation: Fraioli V, Sanvitti M, Bilotta F. MicroRNAs in sepsis: Advances in diagnosis and prognostic monitoring. World J Crit Care Med 2026; 15(1): 114225
- URL: https://www.wjgnet.com/2220-3141/full/v15/i1/114225.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v15.i1.114225
